Immune Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Immune Therapeutics, Inc.

Immune Therapeutics, Inc. is a United States biopharmaceutical company listed in the U.S. market ecosystem commonly referenced by investors as NYSE/NASDAQ, and it is followed largely through SEC disclosures, including Form 4 insider transaction filings. For investors, the company sits squarely in the healthcare and biotech universe, where valuation is typically driven by pipeline optionality, regulatory milestones, financing capacity, and the credibility of management execution rather than by near-term operating scale. From a corporate-history perspective, publicly available market data indicates that the company was formerly known as TNI BioTech, Inc. and adopted the name Immune Therapeutics, Inc. in October 2014. That name change is an important marker for investors reconstructing the company’s evolution, especially in the small-cap biotech space, where restructurings, pivots, and identity changes are common. In practical terms, the most relevant information for market participants tends to come from SEC filings, corporate actions, and any updates on financing, governance, or strategic direction. On the business side, market databases describe Immune Therapeutics as a pharmaceutical and biotechnology company focused on the acquisition, development, and commercialization of products intended to follow a relatively defined path to market. Companies with this profile typically organize around research and development, intellectual property management, clinical or preclinical development, and potential licensing or partnering arrangements. Because public information can be limited and sometimes outdated for microcap issuers, it is prudent not to overstate product readiness or revenue visibility unless verified directly from current SEC documents. In other words, the best reading is to treat the company as a development-stage biotech rather than a mature commercial platform. Competitively, Immune Therapeutics operates in one of the most challenging segments of the U.S. equity market. It competes indirectly with much larger pharmaceutical companies, and directly with numerous emerging biotech firms that may have deeper funding, broader trial networks, or more advanced pipelines. As a result, the stock tends to be highly sensitive to news flow, insider activity, corporate financing, and any regulatory or operational milestone. For French, Belgian, and Swiss investors, that means the company should be analyzed with a strong emphasis on balance-sheet risk, dilution potential, and the significance of each SEC update. Geographically, the company’s footprint is primarily tied to the United States, which is also its country of reference for investors. Available market sources associate the company with Florida, suggesting a U.S.-based corporate presence rather than an established international commercial footprint. Recent items of note are therefore less about large-scale commercial launches and more about governance and disclosure: Form 4 filings, insider purchases or sales, and other SEC-reported events can materially shape investor perception in a company of this size. Overall, Immune Therapeutics should be viewed as a small-cap U.S. biotech with a speculative risk profile, where the key investment question is whether the company can convert its development narrative into durable clinical or commercial value.